resistance to salvage therapy in these cases is related to inherent properties of the mutant PML-RARas or to their presence in clones with increased genetic instability that coincidently, or possibly cooperatively, give rise to alternative resistance-generating molecular aberrations. These results also suggest that testing for RARa-region mutations at first relapse after ATRA/ chemotherapy failure may be of prognostic importance in APL.
The Wilms tumor 1 (WT1) gene, located on chromosome band 11p13, encodes a transcriptional regulator involved in normal hematopoietic development. The WT1 protein contains an N-terminal domain (exons 1-6) and a C-terminal domain with 4 zinc finger motifs (exons 7-10). The role of WT1 in acute leukemia has been underscored by the finding of WT1 overexpression in most cases of acute myeloid leukemia (AML).
1 WT1 mutations have been identified in B10% of patients with AML and have been found to predict poor outcome.
2-4 WT1 mutations in T-lineage acute lymphoblastic leukemia (T-ALL) were first described more than 10 years ago by King-Underwood and Pritchard-Jones 5 in one pediatric case, but were no longer investigated until recently. Our aim was to evaluate the frequency, main associated features and prognostic significance of WT1 mutations in a cohort of children with T-cell malignancies.
A total of 157 children, aged between 7 months and 17 years, with newly diagnosed T-ALL (n ¼ 143) or T-cell lymphoblastic lymphoma (n ¼ 14), were included in this study. Patients were treated according to two consecutive clinical protocols conducted by the CLG-EORTC (Childrens Leukemia Group of the European Organisation for Research and Treatment of Cancer): studies 58881 and 58951. These protocols have been accepted by the EORTC Protocol Review Committee and by the Ethics Committee of each participating center. Informed consent was obtained from the patients or their guardians, in accordance with the declaration of Helsinki. The main characteristics of the T-ALL patients studied are described in Table 1 . T-cell lineage assessment and classification were performed according to the European Group for the Immunological Characterization of Leukemias (EGIL) recommendations. 6 Standard karyotype and screening of MLL rearrangements by fluorescent in situ hybridization analysis were performed at the time of diagnosis. The presence of an overexpression of HOX11/TLX1, HOX11L2/ TLX3 and HOXA10 genes, as well as that of SIL-TAL, CALM-AF10 and NUP214-ABL fusion transcripts was assessed by realtime quantitative reverse transcriptase-PCR as described elsewhere.
7 WT1 expression level was measured by real-time quantitative reverse transcriptase-PCR using the European Leukemia Net Standardized Assay.
1 MYB duplications were detected by gene dosage using real-time quantitative PCR.
8
Mutations of NOTCH1 exons 26, 27, 28 and 34, FBXW7 exons 9 and 10, and WT1 exon 7 and 9 were screened by direct sequencing, as described previously.
3,9,10 Statistical analysis of patient characteristics was performed using the Fisher exact test for binary variables and the Mann-Whitney test for continuous variables. Event-free survival and overall survival were estimated by the Kaplan-Meier method and tested for statistical difference using the Wald test stratified for protocol.
In all, 20 mutations were found in 16 out of 157 (10%) patients with T-cell malignancies, including 15 of 143 T-ALL and 1 of 14 T-cell lymphoblastic lymphoma patients (Table 2 , patient 13). WT1 mutations were predominantly frameshift mutations in exon 7 (19 of 20 cases), consisting of small duplications, deletions or combined insertions/deletions, and were predicted to result in the production of a truncated protein missing the normal zinc finger domains. The remaining mutation was a missense mutation in exon 9 (C388Y), which has been described in the Denys-Drash syndrome.
11 This latter mutation was absent in bone marrow cells at remission, showing that it was somatically acquired in the leukemic clone. Bi-allelic WT1 mutations were found in 4 out of 16 (25%) patients (Table 2 ). All mutated patients showed retention of the two WT1 alleles (no evidence of loss of heterozygosity or deletion was found in WT1 mutated patients, as shown by the heterozygosity of the mutations and/or single-nucleotide polymorphisms detected), suggesting that WT1 may function as a haploinsufficient tumor suppressor gene. During the preparation of this paper, another group, using a single-nucleotide polymorphism array approach, identified deletions and associated mutations in the WT1 gene in T-ALL samples. 12 The frequency of Abbreviations: EGIL, European group for the immunological characterization of leukemias; mut, mutated; ND, not done; T-ALL, T-lineage acute lymphoblastic leukemia; WBC, white blood cell; WT1, Wilms tumor 1. Percentages between ( ) were calculated taking into account only documented cases. *P-value calculated for comparison of early-T versus cortical-T and mature-T.
Letters to the Editor WT1 mutations found in their cohorts (13% of pediatric and 12% of adult T-ALL cases) and the pattern of mutations (mostly exon 7 mutations and only one altered allele) are consistent with our results. We investigated clonal evolution by the analysis of 13 diagnostic-relapse pairs, including 5 T-ALL with the WT1 mutation at initial diagnosis. WT1 mutations present at initial diagnosis were all retained at relapse. One WT1 mutated patient additionally acquired a WT1 mutation at relapse (Table 2 , patient 4) and one of the eight WT1 wild-type patients acquired a heterozygous WT1 mutation at relapse, showing that WT1 mutations can be selected during disease progression.
As shown in Table 1 , WT1 mutated and WT1 wild-type T-ALL patients did not significantly differ in terms of age, gender, white blood cell count or mediastinal involvement. WT1 mutated patients had more frequently an early stage of maturation (46% of WT1 mutated versus 31% of WT1 wild-type T-ALL), but without reaching statistical significance. The expression level of WT1 was significantly higher in WT1 mutated patients (median: 120% (25-837) for WT1 mutants versus 17% (0.007-657) for WT1 wild-type cases, P ¼ 0.004) ( Figure 1 ). As WT1 is preferentially expressed in immature hematopoietic progenitors and downregulated in more differentiated cells, this is in line with the trend for earlier developmental stage arrest observed in the WT1 mutated T-ALL as compared with WT1 wild-type T-ALL cases. Remarkably, HOX11/TLX1 or HOX11L2/TLX3 were overexpressed in 10 of 15 (67%) WT1 mutated T-ALL versus 30 of 128 (23%) WT1 wild-type T-ALL (P ¼ 0.001) cases. In addition, HOXA10 overexpression and MLL-AF6 fusion were found in one WT1 mutated T-ALL each. Overall, direct (overexpression of HOX11, HOX11L2 or HOXA10) or indirect (by a CALM-AF10 fusion or an MLL rearrangement) upregulation of HOX genes could be shown in 12 of 13 (92%) WT1 mutated cases versus only 42 of 105 (40%) WT1 wild-type cases at diagnosis (Po0.001). It is noteworthy that a HOX11L2 overexpression was also found in the T-ALL case that acquired a WT1 mutation at relapse. Despite both lesions being strongly associated with HOX11 and HOX11L2 overexpression in T-ALL, WT1 mutations and NUP214-ABL fusion were found independently. No association was found between the presence of WT1 mutations and NOTCH-activating lesions or MYB duplications (Table 1) .
A possible impact of WT1 mutations on outcome was investigated in 143 T-ALL patients treated according to EORTC 58881 or 58951 protocols. Response to a 7-day prephase, minimal residual disease after induction chemotherapy and incidence of very high-risk features were found similar for patients Figure 1 Comparison of the Wilms tumor 1 (WT1) expression levels between WT1 mutated and wild-type T-lineage acute lymphoblastic leukemia (T-ALL) patients. wt, wild-type; mut, mutant. It is noteworthy that the quantification of WT1 expression level was retrospectively performed in 34 T-ALL patients for whom frozen material was available.
Letters to the Editor with WT1 mutated and WT1 wild-type T-ALL (Table 1) . In all, 26 out of 143 patients subsequently relapsed. No significant differences were found between the WT1 mutated and wild-type group regarding the 5-year event-free survival (77 versus 74%; Wald test stratified for protocol: P ¼ 0.82) and the 5-year overall survival (86 versus 81%; P ¼ 0.75) (Figure 2 ). Although our study may lack statistical power given the small number of events within the WT1 mutated group, these data are consistent with the observation that HOX11L2 overexpression, which is found in half of WT1 mutated T-ALL, has no prognostic impact on the outcome in EORTC trials.
7 This is also in agreement with the results from Tosello et al.
12 in different pediatric protocols. Taken together, these data indicate that WT1 mutations are a recurrent genetic event in pediatric T-ALL and that the incidence and types of mutations are very similar to findings in AML, suggesting common mechanisms between T-ALL and AML pathogenesis. However, WT1 mutations do not confer adverse prognosis in T-ALL, in contrast to what is reported in AML.
2-4
Interestingly, WT1 mutations in T-ALL appear to be highly associated with oncogenic alterations that deregulate HOX genes, suggesting that these abnormalities may be functionally linked in the development or progression of the disease.
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The authors declare no conflict of interest. XAF-1 exists as a single gene with eight exons, which localizes to chromosome 17p13.2, a region just telomeric to the p53 gene. 1 Although XAF-1 has been shown to have a potent proapoptotic activity and to act as a tumor suppressor in several solid tumors by inhibiting X-linked inhibitor of apoptosis at the mitochondrial level, 2 its potential role in hematological malignancies has not been addressed. As 17p-deletion has been associated with poor prognosis in patients affected by B chronic lymphocytic leukemia (B-CLL), 3 we have analyzed the steady-state messenger RNA (mRNA) levels of XAF-1 in a cohort of B-CLL samples, characterized for CLL-associated chromosomal aberrations using fluorescence in situ hybridization (FISH), Zap70 levels and p53 status (Table 1) . Fifteen patient samples showed a monoallelic p53 deletion associated to 17pÀ (p53 deleted). Five patient samples with 17pÀ also carried the p53 mutation (p53 mutated) in the remaining allele (patients 11-12; 14-16 of Table 1 ), while one patient sample showed p53 mutation without detectable defects on 17p at FISH analysis (patient 10 of Table 1 ). When assayed ex vivo for cytotoxic response to 10 mM of the non-genotoxic activator of the p53 pathway 4 B-CLL samples showed a variable susceptibility to Nutlin-3 cytotoxicity upon 48 h of treatment (Table 1 del/mut (median cell viability of 69%, mean ± s.d.: 69.3 þ 13.8). In order to compare the levels of expression of XAF-1 in these two groups, the amount of mRNA was assessed using the real-time thermal analyzer RotorGeneTM 6000 (Corbett, Cambridge, UK) by using SYBR Green based-technology and the reverse transcriptase-polymerase chain reaction primer sets specific for the indicated human cDNA (SABioscience, Frederick, MD, USA). The steady-state XAF-1 mRNA levels were significantly (Po0.05) lower in p53 del/mut (median: 2.6, mean þ s. (500 U/ml) induced a comparable, significant increase (Po0.01) in XAF-1 mRNA steady-state levels in both cell lines (Figure 1b) , and significantly (Po0.05) upregulated Nutlin-3 cytotoxicity not only in SKW6.4 and BJAB but also in primary B-CLL samples ( Figure 1c ). As these data suggested that increased levels of XAF-1 expression might have an important role in sensitizing leukemic cells to Nutlin-3-mediated apoptosis, in the last group of experiments XAF-1 expression was attenuated using a small interfering RNA (siRNA) transfection approach. For this purpose, SKW6.4 cells (1.25 Â 10 6 ) were resuspended into 0.1 ml of Nucleofector solution V of the human nucleofector kit V (Amaxa, Cologne, Germany). A pool of three target-specific 20-25 nt siRNAs (human XAF1 siRNA), as well as a cocktail of three different negative control siRNAs (control siRNA), each comprising a 20-25-nt scrambled sequence that will not lead to the specific degradation of any known cellular mRNA, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The efficiency and specificity of the XAF-1 knockdown were documented in preliminary experiments by a significant decrease of the steady-state mRNA XAF-1 levels in SKW6.4 cells transfected with siRNA for XAF-1 but not in cells transfected with control scrambled siRNA (data not shown). Of note, in SKW6.4 samples in which XAF-1 expression was knocked down by transfection with XAF-1-specific siRNAs, the cytotoxicity of Nutlin-3 plus IFN-b was significantly (Po0.05) lower with respect to either cells transfected with a scrambled control siRNA or cells not transfected (Figure 1d ).
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Our data suggest that XAF-1 might represent an important determinant in modulating the cytotoxic activity of Nutlin-3 and probably also of other pro-apoptotic drugs in B-CLL cells. In fact, p53 del/mut B-CLL samples, which are less responsive to chemotherapeutic or Nutlin-3 treatment than p53 wt B-CLL samples, showed low levels of XAF-1 mRNA. Moreover, modulating the steady-state mRNA levels of XAF-1 through IFN-b treatment or silencing the XAF-1 gene significantly affected the Nutlin-3-mediated cytotoxicity in selected samples of primary p53 wt and p53 del/mut B-CLL as well as in leukemic cell lines. Our current findings are interesting also in light of previous data showing that XAF-1 is a natural antagonist of the inhibitor of apoptosis family proteins, 2 which are believed to contribute to cancer progression and to decrease the sensitivity to drug and radiation therapy. In a recent study, Steele et al. 7 showed that the transcriptional blockade of p53 through pifithrin-a (PFTa) increases the Nutlin-3 ability to induce apoptosis facilitating the translocation of p53 to mitochondria. Thus, future studies should be aimed at evaluating whether permissive levels of XAF-1 are necessary for an optimal p53-mediated cytotoxic activity at the mitochondrial level. It
